ABCB1 polymorphism in clopidogrel-treated Montenegrin patients

Area of Science:

• Pharmacogenomics
• Cardiovascular Medicine
• Molecular Biology

Background:

• Clopidogrel response varies significantly among individuals.
• P-glycoprotein (P-gp), encoded by the ABCB1 gene, influences clopidogrel bioavailability.
• The ABCB1 gene is highly polymorphic, potentially impacting drug efficacy.

Purpose of the Study:

• To investigate the association between ABCB1 genetic polymorphisms and clopidogrel efficacy and safety.
• To determine the frequency distribution of common ABCB1 single nucleotide polymorphisms (SNPs) in a Montenegrin population.
• To assess the clinical implications of ABCB1 variations on antiplatelet therapy outcomes.

Main Methods:

• Genotyping of ABCB1 SNPs (rs1128503, rs2032582, rs1045642) using real-time PCR.
• Clinical follow-up of 106 cardiology patients for 1 year post-hospitalization.
• Monitoring for clopidogrel lack of efficacy and adverse drug reactions.

Main Results:

• Variant allele frequencies for rs1128503, rs2032582, and rs1045642 were 42.9%, 44.8%, and 52.8%, respectively.
• Lack of efficacy and adverse drug reactions were observed in 10.4% and 7.5% of patients, respectively.
• No statistically significant association was found between the studied ABCB1 genotypes and clopidogrel efficacy (p=0.253) or safety (p=0.424).

Conclusions:

• The study did not find a significant correlation between common ABCB1 genotypes and clopidogrel efficacy or safety in this cohort.
• The absence of correlation may be influenced by small sample size, concomitant medications, and unexamined genetic factors.
• Larger, well-controlled studies are recommended to further elucidate the role of ABCB1 polymorphisms in clopidogrel response.